(NASDAQ: CORT) Corcept Therapeutics's forecast annual revenue growth rate of 39.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Corcept Therapeutics's revenue in 2026 is $830,813,000.On average, 7 Wall Street analysts forecast CORT's revenue for 2026 to be $126,367,026,093, with the lowest CORT revenue forecast at $119,664,925,479, and the highest CORT revenue forecast at $131,447,650,752. On average, 7 Wall Street analysts forecast CORT's revenue for 2027 to be $187,983,112,383, with the lowest CORT revenue forecast at $162,471,890,691, and the highest CORT revenue forecast at $234,033,029,505.
In 2028, CORT is forecast to generate $240,627,031,722 in revenue, with the lowest revenue forecast at $190,469,375,514 and the highest revenue forecast at $322,889,911,839.